Simulations Plus (NASDAQ:SLP) Releases FY25 Earnings Guidance

by · The Cerbat Gem

Simulations Plus (NASDAQ:SLP – Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $1.07 to $1.20 for the period, compared to the consensus estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

Simulations Plus stock traded down $3.15 during mid-day trading on Thursday, reaching $30.83. 471,607 shares of the company were exchanged, compared to its average volume of 128,168. The firm has a market cap of $616.91 million, a PE ratio of 64.17 and a beta of 0.69. The firm’s 50-day simple moving average is $33.31 and its two-hundred day simple moving average is $40.83. Simulations Plus has a twelve month low of $29.37 and a twelve month high of $51.22.

Analysts Set New Price Targets

Several brokerages have issued reports on SLP. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday. KeyCorp started coverage on shares of Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price objective for the company. JMP Securities began coverage on Simulations Plus in a report on Tuesday, July 16th. They issued a “market perform” rating on the stock. BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Craig Hallum restated a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a research note on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Simulations Plus has a consensus rating of “Moderate Buy” and a consensus target price of $54.50.

View Our Latest Research Report on SLP

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the director now directly owns 3,501,592 shares of the company’s stock, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 60,750 shares of company stock worth $2,145,055. Company insiders own 20.90% of the company’s stock.

About Simulations Plus

(Get Free Report)

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

Read More